Delving into the Latest Updates on Chimpanzee adenovirus HBV vaccine(GlaxoSmithKline Plc) with Synapse

Overview

Basic Info

Drug Type

Recombinant vector vaccine, Prophylactic vaccine

Synonyms

Recombinant chimpanzee adenovirus type 155 HBV vaccine

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication-

Inactive Indication

Hepatitis BHepatitis B, Chronic

Originator Organization

GSK Plc

Active Organization-

Inactive Organization

GSK Plc

License Organization-

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

A first-time-in Human (FTIH), Phase I/II, Randomized, Multi-centric, Single-blind, Controlled Dose-escalation Study to Evaluate the Reactogenicity, Safety, Immunogenicity and Efficacy of GSK Biologicals' HBV Viral Vector Vaccines Given in a Prime-boost Schedule With Sequential or Co-administration of Adjuvanted Proteins Therapeutic Vaccine (GSK3528869A) in Chronic Hepatitis B Patients (18-65 Years Old) Well Controlled Under Nucleo(s)Tide Analogue (NA) Therapy

A First-Time-In-Human study on GSK's therapeutic vaccines to evaluate the reactogenicity, safety, immunogenicity and efficacy on reduction of serum HBV surface antigen in HBV suppressed subjects under nucleo(s)tide treatment.

Start Date28 Mar 2019

Sponsor / Collaborator

GSK Plc

EUCTR2017-002574-39-DE

/ Not yet recruitingPhase 1/2

Ancillary study evaluating ChAd155-hIi-HBV shedding in a subset of chronic hepatitis B patients enrolled in the first-time-in-human, Phase I/II, randomised, multi-centric, single-blind study TH HBV VV-001 - TH HBV VV-031 HBS:001

Start Date08 Nov 2018

Sponsor / Collaborator

GlaxoSmithKline Biologicals SA

100 Clinical Results associated with Chimpanzee adenovirus HBV vaccine(GlaxoSmithKline Plc)

Login to view more data

100 Translational Medicine associated with Chimpanzee adenovirus HBV vaccine(GlaxoSmithKline Plc)

Login to view more data

100 Patents (Medical) associated with Chimpanzee adenovirus HBV vaccine(GlaxoSmithKline Plc)

Login to view more data

4

Literatures (Medical) associated with Chimpanzee adenovirus HBV vaccine(GlaxoSmithKline Plc)

01 Oct 2014·Nature MedicineQ1 · MEDICINE

Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge

Q1 · MEDICINE

Article

Author: Lingshu Wang ; Adele Abbate ; Virginia Ammendola ; Cheng Cheng ; Anna N Honko ; Mitzi M Donaldson ; Riccardo Cortese ; Stefano Colloca ; Fabiana Grazioli ; Clement Asiedu ; Richard A Koup ; Nancy J Sullivan ; Joshua C Johnson ; Kathryn E Foulds ; Annie W Lau-Kilby ; John Mascola ; Gary J Nabel ; Antonella Folgori ; Alfredo Nicosia ; Mario Roederer ; Daphne A Stanley ; John C Trefry ; Lisa Hensley

Ebolavirus disease causes high mortality, and the current outbreak has spread unabated through West Africa. Human adenovirus type 5 vectors (rAd5) encoding ebolavirus glycoprotein (GP) generate protective immunity against acute lethal Zaire ebolavirus (EBOV) challenge in macaques, but fail to protect animals immune to Ad5, suggesting natural Ad5 exposure may limit vaccine efficacy in humans. Here we show that a chimpanzee-derived replication-defective adenovirus (ChAd) vaccine also rapidly induced uniform protection against acute lethal EBOV challenge in macaques. Because protection waned over several months, we boosted ChAd3 with modified vaccinia Ankara (MVA) and generated, for the first time, durable protection against lethal EBOV challenge.

08 Sep 2014·BMJ

First Ebola treatment is approved by WHO

Author: Gulland, Anne

Serum from people who are convalescing from infection with the Ebola virus can be used to treat new patients, the World Health Organization announced last week. At the end of a two day meeting of around 200 international experts, including regulators, ethicists, virologists, and health workers, WHO approved the use of convalescent serum and whole blood products to treat affected patients in a bid to control the outbreak that has spread through west Africa at an unprecedented rate.1 2 WHO also announced that two promising candidate vaccines, chimpanzee adenovirus vaccine and vesicular stomatitis virus, may be introduced as early as November when safety studies have concluded. Marie-Paule Kieny, assistant director general of WHO, told a press conference that the infrastructure to develop blood products needed to be put in place in the …

01 Mar 2006·VirologyQ3 · MEDICINE

Chimpanzee adenovirus vaccine protects against Zaire Ebola virus

Q3 · MEDICINE

Article

Author: Guangping Gao ; Gregory Schumer ; Steven Jones ; Yan Zhi ; James M. Wilson ; Heinz Feldmann ; Friederike Feldmann ; Gary P. Kobinger

This study evaluated the use of a chimpanzee-based adenovirus vaccine in mouse and Guinea pigs models of Zaire Ebola virus (ZEBOV) infection. Vaccine vector expressing the envelope glycoprotein of ZEBOV was created from the molecular clone of chimpanzee adenovirus pan7 (AdC7). AdC7 vaccine stimulated robust T and B cell responses to ZEBOV in naïve mice inducing complete protection to an otherwise lethal challenge of ZEBOV. Complete protection to Zaire Ebola virus was also observed in Guinea pigs vaccinated with a relatively low dose of AdC7 (5 x 10(9)/kg). Pre-existing immunity to AdHu5 was generated in mice following pre-exposure to AdHu5 or administration of pooled human immune globulin. Pre-existing immunity to human adenoviruses severely compromised the efficacy of the human AdHu5 vaccine but not the chimpanzee AdC7 vaccine. These results validate further development of Chimpanzee-based vaccine and highlight the impact of pre-existing immunity to the vaccine carrier.

100 Deals associated with Chimpanzee adenovirus HBV vaccine(GlaxoSmithKline Plc)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis B	Phase 2	United Kingdom	GSK Plc	27 Jun 2021
Hepatitis B, Chronic	Phase 2	France	GSK Plc	28 Mar 2019
Hepatitis B, Chronic	Phase 2	Belgium	GSK Plc	28 Mar 2019
Hepatitis B, Chronic	Phase 2	Spain	GSK Plc	28 Mar 2019
Hepatitis B, Chronic	Phase 2	Germany	GSK Plc	28 Mar 2019
Hepatitis B, Chronic	Phase 2	Thailand	GSK Plc	28 Mar 2019
Hepatitis B, Chronic	Phase 2	United Kingdom	GSK Plc	28 Mar 2019
Hepatitis B, Chronic	Phase 2	China	GSK Plc	28 Mar 2019